Purchases through the above links give commission which helps fund this website
Recent literature: SGLT-2 inhibitor
Date Journal Article title
2019 Nov Diabetes Obes Metab Effect of Dapagliflozin, a Sodium-glucose Cotransporter-2 Inhibitor, on Gluconeogenesis in Proximal Renal Tubules.
2019 Nov Endokrynol Pol Excess weight loss in a patient with type 2 diabetes mellitus treated with an SGLT- 2 inhibitor.
2019 Oct J Med Econ Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
2019 J Assoc Physicians India Efficacy and Safety of Canagliflozin in Patients with Type II Diabetes Mellitus Inadequately Controlled on Triple Drug Therapy.
2019 Aug Cureus Sudden-onset Hypoglycemia Following Fluid Replacement in a Patient with Dapagliflozin-induced Diabetic Ketoacidosis Without Prior Insulin Use: Case Report.
2019 Aug Diabetes Res Clin Pract The right place for Sulphonylureas today: Part of review the series: Implications of recent CVOTs in Type 2 diabetes mellitus.
2019 Heart Fail Clin Heart Failure and Changes in Kidney Function: Focus on Understanding, Not Reacting.
2019 Jun Can J Diabetes Exploring the Experiences of Adults With Type 2 Diabetes on Sodium Glucose Cotransporter 2 Inhibitors.
2019 Expert Opin Pharmacother The efficacy and safety of luseogliflozin and sitagliptin depending on the sequence of administration in patients with type 2 diabetes mellitus: a randomized controlled pilot study.
2019 Adv Ther Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
2019 Am J Ther Acute Renal Failure With Cocaine and SGLT-2 Inhibitor.
2019 Aug Diabetes Obes Metab Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors.
2019 PLoS One National ambulatory care non-insulin antidiabetic medication prescribing trends in the United States from 2009 to 2015.
2019 Aug Diabetes Obes Metab Effects of sodium-glucose cotransporter-2 inhibitors on the cardiovascular and renal complications of type 2 diabetes.
2019 Jul Ann Intern Med Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study.
2019 Medicine (Baltimore) Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
2019 J Family Med Prim Care Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure.
2019 Kidney Int SGLT2 inhibitors' interaction with other renoactive drugs in type 2 diabetes patients: still a lot to learn.
2019 Arterioscler Thromb Vasc ... SGLT-2 (Sodium-Glucose Cotransporter 2) Inhibition Reduces Ang II (Angiotensin II)-Induced Dissecting Abdominal Aortic Aneurysm in ApoE (Apolipoprotein E) Knockout Mice.
2019 Diabetes Ther Managing Cardiovascular Risk in Type 2 Diabetes: What Do the Cardiovascular Outcome Trials Mean for Australian Practice?
2019 Case Rep Endocrinol A Case of Severe Acute Kidney Injury Exacerbated by Canagliflozin in a Patient with Type 2 Diabetes.
2019 Front Endocrinol (Lausanne) Clinical Use of DPP-4 Inhibitors.
2019 Kyobu Geka [Euglycemic Diabetic Ketoacidosis Caused by a Sodium-glucose Co-transporter (SGLT) 2 Inhibitor after Coronary Artery Bypass Grafting].
2019 Diabetes Obes Metab Use of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations.
2019 Jun World J Diabetes Prevention of macrovascular complications in patients with type 2 diabetes mellitus: Review of cardiovascular safety and efficacy of newer diabetes medications.
2019 Ann Pharmacother The Effect of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in Patients Prescribed Regular U-500 Insulin.
2019 Jun Intern Med Inter-organ Communication Pathway Manifested by Non-physiological Stress to the Kidney in Type II Diabetic Patients -Why Are Diabetic Patients Prone to Develop Heart Failure?
2019 Diabetes Obes Metab Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis.
2019 Iran J Basic Med Sci Empagliflozin alleviates renal inflammation and oxidative stress in streptozotocin-induced diabetic rats partly by repressing HMGB1-TLR4 receptor axis.
2019 Expert Opin Drug Saf An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors.
2019 Diabetes Obes Metab Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials.
2018 Jun Rev Cardiovasc Med Inhibition of the Sodium-Proton Antiporter (Exchanger) is a Plausible Mechanism of Potential Benefit and Harm for Drugs Designed to Block Sodium Glucose Co-transporter 2.
2018 Jun Rev Cardiovasc Med Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review.
2019 Diabetes Obes Metab Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: A meta-analysis of randomized controlled trials.
2019 Diabetes Obes Metab Eligibility of patients with type 2 diabetes for sodium-glucose co-transporter-2 inhibitor cardiovascular outcomes trials: An assessment using the Diabetes Collaborative Registry.
2019 Apr BMJ Case Rep Very low carbohydrate diet and SGLT-2-inhibitor: double jeopardy in relation to ketoacidosis.
2019 J Diabetes Sci Technol A Case Report of Diabetic Ketoacidosis With Combined Use of a Sodium Glucose Transporter 2 Inhibitor and Hybrid Closed-Loop Insulin Delivery.
2019 Diabetologia No direct effect of SGLT2 activity on glucagon secretion.
2019 Diabetes Care Ambulatory Blood Pressure Reduction With SGLT-2 Inhibitors: Dose-Response Meta-analysis and Comparative Evaluation With Low-Dose Hydrochlorothiazide.
2019 Mar Brain Sci Empagliflozin Ameliorates Type 2 Diabetes-Induced Ultrastructural Remodeling of the Neurovascular Unit and Neuroglia in the Female idbiidbi Mouse.
2019 Expert Opin Pharmacother An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes.
2019 Lancet Diabetes Endocrinol Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
2019 Feb Cardiovasc Diabetol Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.
2019 Endocrinol Diabetes Metab Sodium-glucose cotransporter 2 inhibitor plus pioglitazone vs pioglitazone alone in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.
2019 Metabolism Beyond glycemic control: New guidance on cardio-renal protection.
2019 Cell Physiol Biochem Effects of the SGLT-2 Inhibitor Canagliflozin on Adenine-Induced Chronic Kidney Disease in Rats.
2019 Feb World J Diabetes SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review.
2019 Diabetes Metab Syndr Obes Canagliflozin review - safety and efficacy profile in patients with T2DM.
2019 Curr Med Res Opin The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
2019 Feb Acta Cardiol Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes.
2019 Expert Rev Endocrinol Metab Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes.
2019 Prim Care Diabetes Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
2019 Diabetes Obes Metab FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later.
2019 J Diabetes Investig Effects of ipragliflozin on glycemic control, appetite and its related hormones: A prospective, multicenter, open-label study (SOAR-KOBE Study).
2019 Jan Curr Diab Rep Mineralocorticoid Antagonism and Diabetic Kidney Disease.
2019 CEN Case Rep Two cases of advanced stage rapidly progressive diabetic nephropathy effectively treated with combination therapy including RAS blocker, GLP-1 receptor agonist and SGLT-2 inhibitor.
2018 J Pancreat Cancer Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter 2 Inhibitor Use in Two Patients Undergoing Pancreatectomy.
2019 J Clin Med Res Residual Effect of Sodium Glucose Cotransporter 2 Inhibitor, Tofogliflozin, on Body Weight After Washout in Japanese Men With Type 2 Diabetes.
2018 Curr Pharm Biotechnol Hyperglycemia and Diabetes Induced by Glucocorticoids in Nondiabetic and Diabetic Patients: Revision of Literature and Personal Considerations.
2018 Nov Circulation 24-Hour Blood Pressure-Lowering Effect of an SGLT-2 Inhibitor in Patients with Diabetes and Uncontrolled Nocturnal Hypertension: Results from the Randomized, Placebo-Controlled SACRA Study.
2019 Endocr Metab Immune Disor... The Possible Effects of Dapagliflozin on 12-derived Electrocardiogram in Patients with Type 2 Diabetes Mellitus.
2018 Diabetol Metab Syndr Evaluating the Diabetes-Cardiology interface: a glimpse into the diabetes management of cardiology inpatients in western Sydney's 'diabetes hotspot' and the establishment of a novel model of care.
2019 Jan Clin J Am Soc Nephrol Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis.
2019 Biomed Pharmacother SGLT-2 inhibitors reduce glucose absorption from peritoneal dialysis solution by pressing the activity of SGLT-2.
2018 Clin Kidney J The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.
2019 Ann Pharmacother Ertugliflozin: A New Option in the SGLT-2 Inhibitor Market for the Treatment of Type 2 Diabetes Mellitus.
2019 Ann Pharmacother Adjunct Antihyperglycemic Agents in Overweight and Obese Adults With Type 1 Diabetes.
2015 Oct Pharmacoeconomic Review R...
2019 Mol Metab SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
2018 Nov Curr Diab Rep The Evolving Role of the Cardiologist in the Management of Type 2 Diabetes.
2018 Int J Endocrinol Newer Perspectives of Mechanisms for Euglycemic Diabetic Ketoacidosis.
2018 Cardiovasc Drugs Ther Dapagliflozin Attenuates Na+H+ Exchanger-1 in Cardiofibroblasts via AMPK Activation.
2018 J Community Hosp Intern M... Perioperative genitourinary infection associated with sodium-glucose co-transporter 2 inhibitor use.
2017 Sep New Drugs for Type 2 Diab...
2019 Drug Res (Stuttg) Effect of Canagliflozin on Heart Function Involving Ketone Bodies in Patients with Type 2 Diabetes.